Use of mupirocin ointment in the treatment of secondarily infected dermatoses.
A double-blind, randomized, vehicle-controlled study was conducted to evaluate the safety and efficacy of 2% mupirocin ointment in the treatment of secondarily infected dermatoses. One hundred six patients were enrolled, 92 of whom were evaluable for efficacy. There was a significantly greater rate of eradication of Staphylococcus aureus and total pathogens in mupirocin-treated patients than in control subjects. Analysis of the clinical data relative to all pathogens showed a significant difference in skin infection evaluations performed at the interim and follow-up visits, which favored the mupirocin-treated groups. In those patients infected with S. aureus or Streptococcus pyogenes, there was a significant difference at end-point that favored mupirocin in seven clinical ratings and the skin infection evaluation at follow-up. Mild local adverse effects were noted in a small percentage of patients in each group. Mupirocin appears to be safe and effective for the treatment of secondarily infected dermatoses, especially in those infections caused by Staphylococcus aureus.
Breneman
D L
DL
Department of Dermatology, University of Cincinnati Medical Center, OH.
D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D003872:Dermatitis / Q000188:drug therapy* / Q000382:microbiology; D004311:Double-Blind Method; D005227:Fatty Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D016712:Mupirocin; D009824:Ointments; D016032:Randomized Controlled Trials as Topic; D013207:Staphylococcal Skin Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus; D013290:Streptococcal Infections / Q000188:drug therapy; D013297:Streptococcus pyogenes
D000900:Anti-Bacterial Agents; D005227:Fatty Acids; D009824:Ointments; D016712:Mupirocin